D.E. Shaw & Co’s Pacira BioSciences PCRX Stock Holding History

D.E. Shaw & Co’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,600	Closed	-$256K	–	3720
2017 Q4	$256K	Buy	+5,600	New	+$222K	﹤0.01%	3315
2015 Q1	–	Sell	-10,000	Closed	-$887K	–	3905
2014 Q4	$887K	Sell	10,000 -2,500	-20%	-$236K	﹤0.01%	2915
2014 Q3	$1.21M	Buy	12,500 +10,000	+400%	+$973K	﹤0.01%	2647
2014 Q2	$230K	Sell	2,500 -11,300	-82%	-$860K	﹤0.01%	3932
2014 Q1	$966K	Hold	13,800	–	–	﹤0.01%	3053
2013 Q4	$793K	Buy	+13,800	New	+$726K	﹤0.01%	3367

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's PCRX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Pacira BioSciences (PCRX) stake by 2.8% in Q1 2026, selling an estimated $1.27M and leaving 1,982,724 shares worth $44.8M. The position accounts for 0.03% of the portfolio, ranked #708.

D.E. Shaw & Co first reported a position in PCRX in Q2 2013 and has held it in 40 quarters since. The position peaked at $56.3M in Q1 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

D.E. Shaw & Co held 1,982,724 shares of Pacira BioSciences worth $44.8M as of Q1 2026.
D.E. Shaw & Co sold 57,203 Pacira BioSciences shares in Q1 2026, an estimated $1.27M.
Pacira BioSciences made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #708 holding.
D.E. Shaw & Co first reported a position in Pacira BioSciences in Q2 2013 and has held it in 40 quarters since.
D.E. Shaw & Co's Pacira BioSciences position peaked at $56.3M in Q1 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.